PRTN3 and pancreatic serous cystadenoma: The role of anti-PR3 has also been investigated as a potential biomarker for concurrent inflammatory bowel disease in patients with PSC, but not all studies have established a correlation (Stinton et al., 2014; Lee et al., 2019).